Grifols: Invest Securities maintains 'buy', cuts target

(CercleFinance.com) - Invest Securities on Friday reiterated its "buy" rating on Grifols, with a target price reduced from 26 to 23 euros, after the Spanish health company, at a conference, denied rumours of a capital increase that had appeared in the press the night before.


The analyst believes that Grifols wishes to resort to its habitual leverage strategies to reduce its debt.

But for the rest, the group's presentations primarily focused on the business, and in particular on the biotest pipeline, which the analyst considers "attractive".

Copyright (c) 2022 CercleFinance.com. All rights reserved.
The information and analyses distributed by Cercle Finance are only intended as decision-making support for investors. Cercle Finance's responsibility may not be entailed, either directly or indirectly following the use of such information and analyses by readers. Any non-professional investor is recommended to consult a professional advisor before making any investment decision. This indicative information in no way constitutes any invitation to sell or buy securities.